Form 4 for DXCM Dexcom
Accepted 2025-05-27 00:00:00 ET · period of report 2025-05-22 · accession 0001093557-25-000195 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-27 | 2025-05-22 | DXCM | Coleman Jon | EVP, Chief Commercial Off | A - Grant | $0.00 | +68.7K | 68.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-22 | A | A | 68,738 | $0.00 | 68,738 | D | — | — | (F1) Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in four equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. |